In most lung cancers, one main mechanism of cancer cell resistant is the so-called non-pump drug resistance that is primarily due to the activation of anti-apoptotic cellular defense of lung cancer cells, and Bcl-2 is thought to be a key player in this defense [10], [25]. This evidence concerns the gene BCL2 and lung cancer.